Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.42 |
| ▸ | CTSL | P07711 | 7/20 | 0.42 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP7 | P09237 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376979 | 0.94 | CTSK (0.44) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7384628 | 0.91 | MMP1 (0.40) | CTSKCTSLCTSSCTSBMMP1 | |
| SCHEMBL7384308 | 0.82 | MMP1 (0.40) | CTSKCTSLCTSSCTSBMMP1 | |
| SCHEMBL8764249 | 0.80 | MMP1 (0.45) | CTSKCTSLCTSSCTSBMMP1 | |
| SCHEMBL8764718 | 0.80 | MMP1 (0.50) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL6419064 | 0.79 | MMP3 (0.46) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL7384879 | 0.75 | CTSK (0.41) | CTSKCTSLCTSSCTSB | |
| SCHEMBL7384509 | 0.75 | MME (0.45) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL8764735 | 0.75 | MMP3 (0.44) | CTSKCTSLCTSSCTSBMMP1 | |
| SCHEMBL7384528 | 0.75 | CTSK (0.43) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |